Abraxis BioScience, Inc. has plans to split its hospital-based product business, Abraxis Pharmaceutical Products (APP) and Abraxis Oncology and Abraxis Research (the new Abraxis BioScience), into two independent, public companies. According to the company, the transaction would enable each company to compete more effectively in their respective markets. Abraxis will have $1.45 billion of senior credit facilities comprised of a funded $1.3 billion term loan and an unfunded $150 million rev...